Humana Inc. (NYSE:HUM - Get Free Report) gapped up prior to trading on Friday after TD Cowen upgraded the stock from a hold rating to a buy rating. The stock had previously closed at $380.00, but opened at $392.54. TD Cowen now has a $485.00 price target on the stock, up from their previous price target of $430.00. Humana shares last traded at $397.0840, with a volume of 216,814 shares traded.
A number of other research firms have also recently commented on HUM. Bank of America upgraded shares of Humana from a "neutral" rating to a "buy" rating and set a $500.00 target price on the stock in a research note on Wednesday, July 29th. Wall Street Zen upgraded Humana from a "hold" rating to a "buy" rating in a research report on Monday, November 9th. Leerink Partners upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $513.00 target price for the company in a research report on Thursday, July 30th. Raymond James Financial reiterated an "outperform" rating on shares of Humana in a research report on Friday, November 6th. Finally, Jefferies Financial Group restated a "buy" rating and issued a $420.00 target price on shares of Humana in a report on Friday, November 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $491.74.
Check Out Our Latest Stock Report on HUM
Insider Activity at Humana
In other news, insider Joseph Ventura sold 5,495 shares of Humana stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $433.85, for a total transaction of $2,384,005.75. Following the completion of the sale, the insider owned 21,910 shares of the company's stock, valued at approximately $9,505,653.50. The trade was a 20.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.20% of the company's stock.
Top Humana Stories
Investors following HUM have been watching these stories:
- Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $9.50 from $9.05 and its Q1 2028 estimate to $11.72 from $11.53, while maintaining a “Strong Buy” rating. Morgan Stanley also raised its price target to $475 from $370, though it kept an “Equal Weight” rating. MarketBeat Humana coverage
- Neutral Sentiment: Humana plans to bring some employees back to its downtown Louisville offices starting in 2027; the change is not expected to be a major near-term stock driver. Article on Humana office plans
- Negative Sentiment: The proposed CMS CRUSH rule could strengthen Medicare Advantage audits and broaden repayment recoveries, creating regulatory and earnings uncertainty. This policy risk was cited as the driver of a sharp recent decline in Humana shares, despite the company’s improved 2026 earnings outlook. Article on proposed Medicare Advantage audit rules
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the company. Vista Investment Partners LLC acquired a new position in Humana during the 3rd quarter valued at about $3,254,000. Manning & Napier Advisors LLC purchased a new stake in shares of Humana during the second quarter valued at $1,412,000. The Manufacturers Life Insurance Company grew its holdings in shares of Humana by 10.5% during the second quarter. The Manufacturers Life Insurance Company now owns 70,185 shares of the insurance provider's stock valued at $27,879,000 after buying an additional 6,690 shares during the last quarter. Pzena Investment Management LLC acquired a new position in shares of Humana in the 2nd quarter valued at $1,749,014,000. Finally, Ameritas Advisory Services LLC purchased a new position in Humana in the 2nd quarter worth $1,709,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.
Humana Stock Performance
The firm has a market capitalization of $47.57 billion, a price-to-earnings ratio of 38.73, a PEG ratio of 1.84 and a beta of 0.65. The firm's 50 day simple moving average is $409.87 and its 200 day simple moving average is $321.41. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.65 and a current ratio of 1.65.
Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.00) by $0.30. Humana had a net margin of 0.81% and a return on equity of 8.50%. The company had revenue of $41.16 billion during the quarter, compared to the consensus estimate of $40.87 billion. During the same period in the previous year, the firm posted $3.24 earnings per share. The firm's quarterly revenue was up 26.1% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.500- EPS. Sell-side analysts forecast that Humana Inc. will post 9.66 earnings per share for the current fiscal year.
Humana Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, January 29th. Stockholders of record on Thursday, December 24th will be paid a dividend of $0.8850 per share. This represents a $3.54 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Thursday, December 24th. Humana's dividend payout ratio is presently 34.44%.
Humana Company Profile
(
Get Free Report)
Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.